Neuroblastoma: the association of anatomical tumour site, molecular biology and patient outcomes.
MYCN
molecular biology
neuroblastoma
patient outcome
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
30
12
2020
received:
07
09
2020
accepted:
06
01
2021
pubmed:
29
1
2021
medline:
25
5
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Numerous factors have been identified as carrying prognostic value in neuroblastoma (NB) and therefore incorporated in risk stratification of disease. Here, we investigate the association of anatomical site of NB with molecular biology and clinical outcomes. A total of 117 patients with NB were studied over a 30-year period. Tumour location was confirmed with computed tomography/magnetic resonance imaging. Data on molecular biology were obtained as testing became available. Chi-squared, Fisher's exact test and Kaplan-Meier log-rank tests were used for statistical analysis. Tumour originated in the thoracic region (thoracic NB, TNB) in 15 patients (13%), adrenal gland (adrenal NB, ANB) in 88 patients (75%) and abdominal/paravertebral chain (paravertebral NB, PVNB) in 14 patients (12%). Overall survival (OS) for ANB was significantly lower (38%; P = 0.015). ANB cases were more frequently diagnosed at stage IV (69%; P = 0.001). MYCN amplification was noted in 33% of ANB cases and associated with lower OS (17% versus 62% MYCN non-amplified ANB; P = 0.01). The vast majority of TNB and PVNB were non-MYCN amplified (100% and 86%, respectively) and carried better prognosis (OS 86% and 83%, respectively). Forty-two percent of ANB cases were diploid and had lower OS (20% versus 71% hyperdiploid ANB; P = 0.079). TNB and PVNB were found to be mostly hyperdiploid (86% and 100%, respectively) with better OS (83% and 33%, respectively). Segmental chromosomal alterations had prognostic significance in those with PVNB (P = 0.03). TNB tumours have better outcomes than adrenal tumours. This may be due to varied factors reported here including non-metastatic disease at presentation, non-amplification of the MYCN oncogene and overall favourable molecular biology characteristics.
Sections du résumé
BACKGROUND
Numerous factors have been identified as carrying prognostic value in neuroblastoma (NB) and therefore incorporated in risk stratification of disease. Here, we investigate the association of anatomical site of NB with molecular biology and clinical outcomes.
METHODS
A total of 117 patients with NB were studied over a 30-year period. Tumour location was confirmed with computed tomography/magnetic resonance imaging. Data on molecular biology were obtained as testing became available. Chi-squared, Fisher's exact test and Kaplan-Meier log-rank tests were used for statistical analysis.
RESULTS
Tumour originated in the thoracic region (thoracic NB, TNB) in 15 patients (13%), adrenal gland (adrenal NB, ANB) in 88 patients (75%) and abdominal/paravertebral chain (paravertebral NB, PVNB) in 14 patients (12%). Overall survival (OS) for ANB was significantly lower (38%; P = 0.015). ANB cases were more frequently diagnosed at stage IV (69%; P = 0.001). MYCN amplification was noted in 33% of ANB cases and associated with lower OS (17% versus 62% MYCN non-amplified ANB; P = 0.01). The vast majority of TNB and PVNB were non-MYCN amplified (100% and 86%, respectively) and carried better prognosis (OS 86% and 83%, respectively). Forty-two percent of ANB cases were diploid and had lower OS (20% versus 71% hyperdiploid ANB; P = 0.079). TNB and PVNB were found to be mostly hyperdiploid (86% and 100%, respectively) with better OS (83% and 33%, respectively). Segmental chromosomal alterations had prognostic significance in those with PVNB (P = 0.03).
CONCLUSION
TNB tumours have better outcomes than adrenal tumours. This may be due to varied factors reported here including non-metastatic disease at presentation, non-amplification of the MYCN oncogene and overall favourable molecular biology characteristics.
Substances chimiques
N-Myc Proto-Oncogene Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1000-1004Informations de copyright
© 2021 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.
Références
Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol. Oncol. Clin. North Am. 2010; 24: 65-86.
Cohn SL, Pearson AD, London WB et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 2009; 27: 289-97.
Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 1993; 11: 1466-77.
Shimada H, Umehara S, Monobe Y et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92: 2451-61.
Raitio A, Rice MJ, Mullassery D, Losty PD. Stage 4S neuroblastoma: what are the outcomes? A systematic review of published studies. Eur. J. Pediatr. Surg. 2020. https://doi.org/10.1055/s-0040-1716836.
Maris JM, Weiss MJ, Guo C et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J. Clin. Oncol. 2000; 18: 1888-99.
Attiyeh EF, London WB, Mosse YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 2005; 353: 2243-53.
Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 1999; 340: 1954-61.
Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med. 1984; 311: 231-5.
George RE, London WB, Cohn SL et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 2005; 23: 6466-73.
Rosswog C, Schmidt R, Oberthuer A et al. Molecular classification substitutes for the prognostic variables stage, age, and MYCN status in neuroblastoma risk assessment. Neoplasia 2017; 19: 982-90.
Tomioka N, Oba S, Ohira M et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008; 27: 441-9.
Suita S, Tajiri T, Sera Y et al. The characteristics of mediastinal neuroblastoma. Eur. J. Pediatr. Surg. 2000; 10: 353-9.
Adams GA, Shochat SJ, Smith EI et al. Thoracic neuroblastoma: a Pediatric Oncology Group study. J. Pediatr. Surg. 1993; 28: 372-7.
Häberle B, Hero B, Berthold F, von Schweinitz D. Characteristics and outcome of thoracic neuroblastoma. Eur. J. Pediatr. Surg. 2002; 12: 145-50.
Horiuchi A, Muraji T, Tsugawa C et al. Thoracic neuroblastoma: outcome of incomplete resection. Pediatr. Surg. Int. 2004; 20: 714-8.
Morris JA, Shcochat SJ, Smith EI et al. Biological variables in thoracic neuroblastoma: a Pediatric Oncology Group study. J. Pediatr. Surg. 1995; 30: 296-302.
Losty P, Quinn F, Breatnach F, O'Meara A, Fitzgerald RJ. Neuroblastoma - a surgical perspective. Eur. J. Surg. Oncol. 1993; 19: 33-6.
Sung KW, Yoo KH, Koo HH et al. Neuroblastoma originating from extra-abdominal sites: association with favorable clinical and biological features. J. Korean Med. Sci. 2009; 24: 461-7.
Brisse HJ, Blanc T, Schleiermacher G et al. Radiogenomics of neuroblastomas: relationships between imaging phenotypes, tumor genomic profile and survival. PLoS One 2017; 12: e0185190.
Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 1980; 46: 1896-901.
Cotterill SJ, Pearson AD, Pritchard J et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group 'Survey' 1982-1992. Eur. J. Cancer 2000; 36: 901-8.
Caron HN. Are thoracic neuroblastomas really different? Pediatr. Blood Cancer 2010; 54: 867.
Vo KT, Matthay KK, Neuhaus J et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group project. J. Clin. Oncol. 2014; 32: 3169-76.
Salim A, Mullassery D, Pizer B, McDowell HP, Losty PD. Neuroblastoma: a 20-year experience in a UK regional centre. Pediatr. Blood Cancer 2011; 57: 1254-60.
Cooper MJ, Steinberg SM, Chatten J, Evans AE, Israel MA. Plasticity of neuroblastoma tumor cells to differentiate along a fetal adrenal ganglionic lineage predicts for improved patient survival. J. Clin. Invest. 1992; 90: 2402-8.
Carter R, Mullassery D, See V et al. Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression. Oncogenesis 2012; 1: e24.
Oberthuer A, Hero B, Berthold F et al. Prognostic impact of gene expression-based classification for neuroblastoma. J. Clin. Oncol. 2010; 28: 3506-15.
Molenaar JJ, Koster J, Zwijnenburg DA et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483: 589-93.
Cheung NK, Zhang J, Lu C et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012; 307: 1062-71.
Peifer M, Hertwig F, Roels F et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015; 526: 700-4.
Bosse KR, Maris JM. Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 2016; 122: 20-33.